Geoffrey A Block1, Martha S Block2, Gerard Smits3, Rupal Mehta4, Tamara Isakova5, Myles Wolf6, Glenn M Chertow7. 1. Reata Pharmaceuticals, Dallas, Texas; geoff@goldenblocks.org. 2. Denver Nephrology Research Division, Denver, Colorado. 3. CSC, Inc., Santa Barbara, California. 4. Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute of Public Health and Medicine, Feinberg School of Medicine, Jesse Brown Veterans Administration Medical Center. 5. Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 6. Division of Nephrology, Department of Medicine, and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; and. 7. Stanford University, Palo Alto, California.
Abstract
BACKGROUND: Researchers have yet to determine the optimal care of patients with advanced CKD. Evidence suggests that anemia and CKD-related disordered mineral metabolism (including abnormalities in phosphate and fibroblast growth factor 23 [FGF23]) contribute to adverse outcomes in this population. METHODS: To investigate whether fixed-dose ferric citrate coordination complex favorably affects multiple biochemical parameters in patients with advanced CKD, we randomly assigned 203 patients witheGFR≤20 ml/min per 1.73 m2 2:1 to receive a fixed dose of ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet) or usual care for 9 months or until 3 months after starting dialysis. No single biochemical end point was designated as primary; sample size was determined empirically. RESULTS: The two groups had generally similar baseline characteristics, although diabetes and peripheral vascular disease were more common in the usual-care group. Ferric citrate coordination complex significantly increased hemoglobin, transferrin saturation, and serum ferritin, and it significantly reduced serum phosphate and intact FGF23 (P<0.001 for all). Of the 133 patients randomized toferric citrate coordination complex, 31 (23%) initiated dialysis during the study period, as did 32 of 66 (48%) patients randomized to usual care (P=0.001). Compared with usual care, ferric citrate coordination complex treatment resulted in significantly fewer annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation (P=0.002). CONCLUSIONS: The beneficial effects of fixed-dose ferric citrate coordination complex on biochemical parameters, as well as the exploratory results regarding the composite end point and hospitalization, suggest that fixed-dose ferric citrate coordination complex has an excellent safety profile in an unselected population with advanced CKD and merits further study.
RCT Entities:
BACKGROUND: Researchers have yet to determine the optimal care of patients with advanced CKD. Evidence suggests that anemia and CKD-related disordered mineral metabolism (including abnormalities in phosphate and fibroblast growth factor 23 [FGF23]) contribute to adverse outcomes in this population. METHODS: To investigate whether fixed-dose ferric citrate coordination complex favorably affects multiple biochemical parameters in patients with advanced CKD, we randomly assigned 203 patients with eGFR≤20 ml/min per 1.73 m2 2:1 to receive a fixed dose of ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet) or usual care for 9 months or until 3 months after starting dialysis. No single biochemical end point was designated as primary; sample size was determined empirically. RESULTS: The two groups had generally similar baseline characteristics, although diabetes and peripheral vascular disease were more common in the usual-care group. Ferric citrate coordination complex significantly increased hemoglobin, transferrin saturation, and serum ferritin, and it significantly reduced serum phosphate and intact FGF23 (P<0.001 for all). Of the 133 patients randomized to ferric citrate coordination complex, 31 (23%) initiated dialysis during the study period, as did 32 of 66 (48%) patients randomized to usual care (P=0.001). Compared with usual care, ferric citrate coordination complex treatment resulted in significantly fewer annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation (P=0.002). CONCLUSIONS: The beneficial effects of fixed-dose ferric citrate coordination complex on biochemical parameters, as well as the exploratory results regarding the composite end point and hospitalization, suggest that fixed-dose ferric citrate coordination complex has an excellent safety profile in an unselected population with advanced CKD and merits further study.
Authors: Geoffrey A Block; Martha S Persky; Markus Ketteler; Bryan Kestenbaum; Ravi Thadhani; Laura Kooienga; David Spiegel; John Asplin; James Ehrlich; Vincent Dennis; Allen Nissenson; Glenn M Chertow; David C Wheeler Journal: Hemodial Int Date: 2009-07-07 Impact factor: 1.812
Authors: Helen Eddington; Richard Hoefield; Smeeta Sinha; Constantina Chrysochou; Beverley Lane; Robert N Foley; Janet Hegarty; John New; Donal J O'Donoghue; Rachel J Middleton; Philip A Kalra Journal: Clin J Am Soc Nephrol Date: 2010-08-05 Impact factor: 8.237
Authors: Conall M O'Seaghdha; Shih-Jen Hwang; Paul Muntner; Michal L Melamed; Caroline S Fox Journal: Nephrol Dial Transplant Date: 2011-02-03 Impact factor: 5.992
Authors: Tamara Isakova; Patricia Wahl; Gabriela S Vargas; Orlando M Gutiérrez; Julia Scialla; Huiliang Xie; Dina Appleby; Lisa Nessel; Keith Bellovich; Jing Chen; Lee Hamm; Crystal Gadegbeku; Edward Horwitz; Raymond R Townsend; Cheryl A M Anderson; James P Lash; Chi-Yuan Hsu; Mary B Leonard; Myles Wolf Journal: Kidney Int Date: 2011-03-09 Impact factor: 10.612
Authors: Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto Journal: N Engl J Med Date: 2009-10-30 Impact factor: 91.245
Authors: Danilo Fliser; Barbara Kollerits; Ulrich Neyer; Donna P Ankerst; Karl Lhotta; Arno Lingenhel; Eberhard Ritz; Florian Kronenberg; Erich Kuen; Paul König; Günter Kraatz; Johannes F E Mann; Gerhard A Müller; Hans Köhler; Peter Riegler Journal: J Am Soc Nephrol Date: 2007-07-26 Impact factor: 10.121
Authors: Pablo Florenzano; Macarena Jimenez; Carlos R Ferreira; Galina Nesterova; Mary Scott Roberts; Sri Harsha Tella; Luis Fernandez de Castro; Rachel I Gafni; Myles Wolf; Harald Jüppner; Barbara Gales; Katherine Wesseling-Perry; Daniela Markovich; William A Gahl; Isidro B Salusky; Michael T Collins Journal: J Am Soc Nephrol Date: 2020-07-06 Impact factor: 10.121
Authors: Edwin Patino; Stephen B Doty; Divya Bhatia; Kelly Meza; Yuan-Shan Zhu; Stefano Rivella; Mary E Choi; Oleh Akchurin Journal: Kidney Int Date: 2020-06-20 Impact factor: 10.612
Authors: Nigel D Toussaint; Eugenia Pedagogos; Nicole M Lioufas; Grahame J Elder; Elaine M Pascoe; Sunil V Badve; Andrea Valks; Geoffrey A Block; Neil Boudville; James D Cameron; Katrina L Campbell; Sylvia S M Chen; Randall J Faull; Stephen G Holt; Dana Jackson; Meg J Jardine; David W Johnson; Peter G Kerr; Kenneth K Lau; Lai-Seong Hooi; Om Narayan; Vlado Perkovic; Kevan R Polkinghorne; Carol A Pollock; Donna Reidlinger; Laura Robison; Edward R Smith; Robert J Walker; Angela Yee Moon Wang; Carmel M Hawley Journal: J Am Soc Nephrol Date: 2020-09-11 Impact factor: 10.121
Authors: Rupal C Mehta; Monique E Cho; Xuan Cai; Jungwha Lee; Jing Chen; Jiang He; John Flack; Tariq Shafi; Santosh L Saraf; Valentin David; Harold I Feldman; Tamara Isakova; Myles Wolf Journal: Kidney Int Date: 2021-07-30 Impact factor: 10.612